Comparative Pharmacology
Head-to-head clinical analysis: TORECAN versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TORECAN versus ZUPLENZ.
TORECAN vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TORECAN (thiethylperazine) is a phenothiazine derivative that acts primarily as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) to exert antiemetic effects. It also possesses anticholinergic and antihistaminergic properties.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
10 mg orally or intramuscularly every 6 to 8 hours as needed for nausea and vomiting.
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours. Clinical context: Allows twice-daily dosing; prolonged in renal impairment.
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (20-30%).
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category C
Category C
Antiemetic
Antiemetic